Teladoc Health (TDOC) Projected to Post Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is projected to announce its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Teladoc Health to post earnings of ($0.19) per share and revenue of $635.3290 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Teladoc Health Trading Down 2.8%

TDOC stock opened at $4.75 on Monday. The company has a market capitalization of $842.10 million, a PE ratio of -3.71 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. Teladoc Health has a one year low of $4.40 and a one year high of $12.69. The company’s 50 day moving average price is $6.23 and its two-hundred day moving average price is $7.28.

Insiders Place Their Bets

In related news, insider Adam C. Vandervoort sold 5,720 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares in the company, valued at $604,682.68. This represents a 6.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carlos Nueno sold 3,897 shares of Teladoc Health stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total transaction of $29,188.53. Following the completion of the sale, the insider owned 27,175 shares in the company, valued at approximately $203,540.75. This trade represents a 12.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,288 shares of company stock valued at $251,684 over the last three months. 0.58% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently bought and sold shares of TDOC. Creative Planning grew its holdings in shares of Teladoc Health by 7.7% during the 3rd quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock worth $159,000 after acquiring an additional 1,462 shares during the period. Syon Capital LLC boosted its position in shares of Teladoc Health by 19.1% during the fourth quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock valued at $99,000 after purchasing an additional 2,264 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 2,810 shares in the last quarter. HighTower Advisors LLC grew its stake in Teladoc Health by 19.2% in the fourth quarter. HighTower Advisors LLC now owns 18,647 shares of the health services provider’s stock worth $131,000 after purchasing an additional 2,997 shares during the period. Finally, California State Teachers Retirement System raised its holdings in Teladoc Health by 2.0% in the second quarter. California State Teachers Retirement System now owns 158,537 shares of the health services provider’s stock worth $1,381,000 after purchasing an additional 3,114 shares in the last quarter. 76.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Evercore decreased their target price on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Citigroup lowered their target price on Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, January 9th. Bank of America reduced their price target on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 25th. Finally, Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Teladoc Health has an average rating of “Hold” and an average price target of $9.12.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.